<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274024</url>
  </required_header>
  <id_info>
    <org_study_id>R1293/99/2015</org_study_id>
    <nct_id>NCT03274024</nct_id>
  </id_info>
  <brief_title>The Asia Primary Tube Versus Trab (TVT) Study</brief_title>
  <acronym>TVT</acronym>
  <official_title>The Asia Primary Tube Versus Trab (TVT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore Eye Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Ahmed Glaucoma Implant (AGI) against trabeculectomy with mitomycin C in
      patients with uncontrolled open angle glaucoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the Asia Primary Tube versus Trab (TVT) study is to compare the efficacy and
      safety of placement of an Ahmed Glaucoma Implant (AGI) (New World Medical Inc., Rancho
      Cucamonga, CA, USA) against trabeculectomy with mitomycin C in patients with uncontrolled
      glaucoma, who may or may not have had previous clear corneal cataract surgery with
      intraocular lens implantation, over 5 years. Outcome discrimination between the two treatment
      groups will be made using following parameters:

        1. Intraocular pressure

        2. Need for supplemental medical therapy

        3. Incidence of short and long term surgical complications and need for re-operation.

        4. Visual function (Visual acuity and Visual field)

      Hypothesis: Glaucoma drainage implants have better surgical outcomes in terms of IOP lowering
      efficacy compared to trabeculectomy with mitomycin-C over 5 years in Asian patients with
      medically uncontrolled glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure</measure>
    <time_frame>6 months</time_frame>
    <description>Failure defined by ANY of the following criteria:
IOP ≥ 18 mm Hg on two consecutive follow-up visits after 6 months
IOP not reduced to 20% below baseline on two consecutive visits after 6 months
IOP ≤ 5 mm Hg with visually significant hypotony maculopathy on two consecutive visits after 3 months
Additional glaucoma surgery, excluding laser suture lysis, removal of releasable trabeculectomy or conjunctival sutures, needling of the bleb or tube plate with or without 5FU, subconjunctival 5FU injections and anterior chamber reformation.
Loss of light perception vision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
    <time_frame>60 months</time_frame>
    <description>Intraocular pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>60 months</time_frame>
    <description>ETDRS visual acuity chart (logMAR or equivalent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental medication</measure>
    <time_frame>60 months</time_frame>
    <description>Number of supplemental glaucoma medications used at Month 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>60 months</time_frame>
    <description>Number of Adverse Events during the trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Tube implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ahmed Glaucoma Implant (AGI) surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabeculectomy with mitomycin C surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed Glaucoma Implant</intervention_name>
    <description>Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube</description>
    <arm_group_label>Tube implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy with Mitomycin C</intervention_name>
    <description>Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure</description>
    <arm_group_label>Trabeculectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Open angle glaucoma including primary open angle glaucoma, pseudoexfoliative or
             pigmentary glaucoma.

          2. IOP &gt; 18 mm Hg on 2 or more medications on at least 2 visits

          3. Informed consent given and consent form signed.

        Exclusion Criteria:

          1. Unwilling or unable to give consent, unwilling to accept randomisation, or unable to
             return for scheduled protocol visits.

          2. Pregnant or nursing women

          3. No light perception vision

          4. Previous incisional intraocular surgery, other than uncomplicated clear corneal
             cataract surgery

          5. Previous ocular laser in study eye (keratorefractive surgery and cyclodestructive
             procedure), except for laser trabeculoplasty procedures (Argon Laser and Selective
             Laser Trabeculoplasty)

          6. Iris neovascularisation or proliferative retinopathy

          7. Primary angle closure or primary angle closure glaucoma

          8. Iridocorneal endothelial syndrome or anterior segment dysgenesis

          9. Epithelial or fibrous downgrowth

         10. Aphakia

         11. Chronic or recurrent uveitis

         12. Severe posterior blepharitis

         13. Unwilling to discontinue contact lens use after surgery

         14. Glaucoma secondary to penetrating keratoplasty, trauma, steroids, retinal
             disease/surgery or neovascular disease

         15. Conjunctival scarring from prior ocular surgery, trauma or cicatrizing disease
             precluding a superior trabeculectomy

         16. Need for glaucoma surgery combined with other ocular procedures (i.e. cataract
             surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for urgent
             additional ocular surgery

         17. Advanced glaucoma with MD &lt;-20dB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching Lin Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore National Eye Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalia Porporato, Fellow</last_name>
    <phone>+6591378217</phone>
    <email>natalia.porporato@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ya Ying Ooi</last_name>
    <phone>+658186 7051</phone>
    <email>ooi.ya.ying@seri.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Singapore Eye Research Institute</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Ting</last_name>
      <phone>(+65) 8113 5026</phone>
      <email>serena.ting.m.l@seri.com.sg</email>
    </contact>
    <investigator>
      <last_name>Ching Lin Ho, A/Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singapore Eye Research Institute</investigator_affiliation>
    <investigator_full_name>Dr Ho Ching Lin</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

